Every 8-K that Oramed Pharmaceuticals Inc. (ORMP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ORMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORMP filings page.
ORAMED PHARMACEUTICALS INC. (ORMP) held its 2026 Annual Meeting of Stockholders on September 15, 2026. Stockholders re‑elected all six directors standing for election. They also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the 2026 fiscal year.
Stockholders approved an amendment to the Amended and Restated 2019 Stock Incentive Plan to increase the shares of common stock authorized for issuance under the plan by 3,000,000, to a total of 12,500,000 shares. On a non‑advisory basis, stockholders approved the compensation of named executive officers and selected a three‑year frequency for future say‑on‑pay votes. The board determined that say‑on‑pay votes will be held every three years. An adjournment proposal was rendered moot because all other proposals received sufficient support.
Oramed Pharmaceuticals Inc. updated its corporate bylaws and restructured payment timing on large notes owed by Scilex Holding Company. The board approved Fifth Amended and Restated Bylaws, which adjust how record dates and written stockholder consents are set and delivered.
Separately, Oramed agreed to extend repayment of Scilex’s Obligations under a Senior Secured Promissory Note and a Senior Secured Convertible Note, totaling about $29.5 million on the Tranche A Note and about $6.7 million on the Tranche B Note. Scilex will pay $0.5 million received on June 25, 2026, $5 million by July 31, 2026, and the remaining balance by September 30, 2026, with a mechanism that can recharacterize $1.5 million as an extension fee if full repayment is not made, and a provision to settle remaining amounts in registered common stock of Scilex or an affiliate.
Oramed Pharmaceuticals Inc. completed the sale of its wholly owned subsidiary Oratech Pharma, Inc. to Lifeward Ltd. and closed a related financing on Lifeward securities. In exchange for Oratech, Oramed received 1,250,363 Lifeward ordinary shares, 1,006,113 pre-funded warrants at an exercise price of $0.0001 per share, and warrants to purchase up to 1,296,296 Lifeward shares at $5.40 per share. Oramed will also receive 4% revenue-sharing payments on Lifeward’s ReWalk Personal Exoskeleton products, subject to a 10-year limit, a maximum aggregate amount, or Lifeward reaching a $200 million market capitalization. Separately, Oramed purchased $9,000,000 in senior secured convertible notes from Lifeward, initially convertible at $5.40 per share, plus additional warrants to buy up to 1,666,666 Lifeward shares at $5.40 per share.
Oramed Pharmaceuticals Inc. entered into a new warrant agreement with Scilex Holding Company on February 19, 2026. In return for previously deferring an amortization payment on Scilex’s senior secured convertible Tranche B Notes, Oramed received a February 2026 warrant to purchase 100,000 shares of Scilex common stock at an initial exercise price of $20.00 per share.
The warrant is immediately exercisable and expires on December 13, 2029. Its exercise price is adjustable for stock splits and certain future offerings, but not below a floor price of $8.22. The warrant includes a beneficial ownership cap of 4.99%, which Oramed may raise up to 9.99% with 61 days’ notice. It also contains protections in change-of-control and other fundamental transactions, including a right for Oramed to require cash repurchase of the unexercised portion at its Black Scholes value.
Oramed Pharmaceuticals signed a major deal with Lifeward Ltd. to sell all of its Oratech Pharma subsidiary. In return, Oramed will receive Lifeward ordinary shares, very low-priced pre-funded warrants, and additional warrants that together could give it up to 49.99% of Lifeward’s fully diluted equity, subject to ownership limits and shareholder approval. Oramed will also receive 4% of net revenue from Lifeward’s ReWalk Personal Exoskeleton products until a time or value cap is reached or Lifeward’s market value hits $200 million.
Separately, Oramed agreed to buy $9,000,000 of senior secured convertible notes from Lifeward now, with an option for another $9,000,000 later if performance or share price targets are met. These notes and related warrants are convertible into Lifeward shares at an initial price of $0.45 per share, with anti-dilution adjustments and caps to keep Oramed’s ownership initially below 45.0%. Oramed also committed to a 120‑day lock-up on Lifeward securities it receives and will manage Oratech’s oral insulin clinical study under a reimbursed services agreement.
Oramed Pharmaceuticals Inc. reported that it has received an $18 million payment from Scilex Holdings Inc., which represents full satisfaction of Scilex’s obligations under their Option Agreement. This adds a significant amount of cash to the company.
The company’s board also approved a cash dividend of $0.25 per share to reward stockholders, for a total distribution of approximately $10.5 million based on the current shares outstanding. The dividend will be paid on January 26, 2026 to stockholders of record as of January 16, 2026, and will be funded from the company’s surplus capital.
Oramed Pharmaceuticals Inc. filed a current report announcing that it has released unaudited financial results for the nine months ended September 30, 2025. The company disclosed these results in a press release dated November 17, 2025, which is included as Exhibit 99.1 to the report. The financial information is provided under Item 2.02, meaning it is being furnished rather than filed and therefore is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. Oramed’s common stock continues to trade on The Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.
Oramed Pharmaceuticals Inc. adopted a shareholder rights plan by declaring a dividend of one common stock purchase right for each outstanding share of common stock. The dividend will be paid on November 27, 2025 to holders of record on that date. Each right initially allows the holder to buy one share of common stock from the company at $10.00 per share, subject to adjustment. The rights become separable and trade independently only if a person or group acquires, or launches an offer to acquire, generally 15% or more of Oramed’s common stock. If that happens, other right holders can acquire common stock (or, in some cases, stock of an acquiring company) with a market value equal to two times the exercise price, while the acquiring person’s rights become void. The rights expire three years after the agreement date unless earlier redeemed by the board at $0.012 per right or exchanged for common stock.
Oramed Pharmaceuticals (ORMP) repurchased and retired shares and ended a planned joint venture. On October 20, 2025, the company bought back 1,155,367 shares of its common stock from Hefei Tianhui Biotech Co., Ltd. at $2.23 per share for an aggregate $2,576,468.41. The transaction closed the same day, and the shares were cancelled and retired, reducing the share count.
On October 23, 2025, Oramed terminated its Joint Venture Agreement and a related Supplemental Agreement with HTIT after HTIT was unable to satisfy closing conditions. The company also furnished a shareholder letter with preliminary, unaudited financial information as of September 30, 2025, accompanied by cautionary language noting that results are subject to adjustment and may materially vary.
Oramed Pharmaceuticals Inc. reported that Scilex Holding Company exercised the first tranche of an option to repurchase warrants Oramed holds in Scilex. These warrants allow purchase of Scilex common stock. On September 30, 2025, Scilex repurchased warrants covering 3,130,000 Scilex shares from Oramed for $13,000,000, as part of a previously agreed warrant repurchase transaction totaling up to $27,000,000. Under the option agreement, Scilex may still repurchase the remaining warrants covering 3,370,000 Scilex shares from Oramed for $14,000,000 on or before December 31, 2025.
Oramed Pharmaceuticals Inc. reported results of its 2025 annual stockholders meeting held on August 19, 2025. Stockholders approved an amendment to the company’s Amended and Restated 2019 Stock Incentive Plan, increasing the total number of shares of common stock authorized for issuance under the plan by 2,000,000 shares to 9,500,000 shares. This plan is used to grant equity awards to eligible participants, including officers and directors.
All nominated directors were re-elected to serve until the next annual meeting, with each receiving over 12.4 million votes in favor, subject to varying levels of opposition and broker non-votes. Stockholders also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the company’s independent registered public accounting firm for the 2025 fiscal year.
Oramed Pharmaceuticals (ORMP) filed an 8-K disclosing an Option Agreement signed 22-Jul-25 with Scilex Holding. The accord gives Scilex the right to repurchase Oramed’s remaining 6.5 M “Penny Warrants” (exercise price $0.01/sh) in two tranches for a total cash consideration of $27 M. To secure the option, Scilex will pay Oramed $1.5 M in two equal installments due 8-Aug-25 and 16-Dec-25.
- Tranche 1: up to 3.13 M warrants for $13 M if exercised by 30-Sep-25.
- Tranche 2: up to 3.37 M warrants for $14 M if exercised by 31-Dec-25.
If Scilex completes the repurchase and makes all payments, the maturity of the $101.9 M Tranche A senior secured note held by Oramed will be extended to 31-Mar-26 and its make-whole prepayment penalty waived.
Until the earlier of option expiry or termination, Oramed has agreed not to exercise the warrants. Oramed can terminate the agreement if Scilex misses any payment or fails to exercise by the set dates. Post-termination, Scilex will seek shareholder approval to permit stock issuance above a 19.9 % cap should Oramed later exercise retained warrants.
The filing also clarifies prior disclosure: despite Scilex’s 1-for-35 reverse split, the Penny Warrant exercise price remains $0.01 and the quantity remains 6.5 M shares; no impact to previously reported Q1-25 financials.